Faustine Dalon
Research Subjects
Faustine Dalon has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Eric Van Ganse
PELyon, Lyon, France
3 shared publications Flore Jacoud
PELyon, PharmacoEpidemiologie Lyon, France
2 shared publicationsManon Belhassen
PELyon, PharmacoEpidemiologie Lyon, France
2 shared publications- Manon Belhassen
PELyon, Lyon, France
2 shared publications Camille Correia Da Silva
GlaxoSmithKline France, Pharmaco Epidemiology and Health Economics and Outcomes Research, Rueil-Malmaison, France
1 shared publication- Christos Chouaid
Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 88-95
Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis
- 1 January 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (1) , 88-95
Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1105
Outcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1105
Open AccessOutcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
- Open Access
- 1 December 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 2905-2915
Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
Purpose: This study assessed therapy persistence in patients with chronic obstructive pulmonary disease (COPD) in France, and the impact of non-persistence on exacerbations and described COPD-related healthcare resource use (HRU). Methods: Patients aged ≥45 years who received ≥1 dispensed bronchodilator per quarter over three consecutive quarters between 2007 and 2014 and initiated specific COPD therapy were selected from the Echantillon Généraliste des Bénéficiaires (EGB) database. Persistence, defined as the absence of dispensing gaps of >90 days, was measured at 12 months. Exacerbations were compared between persistent and non-persistent patients during follow-up after patient matching and adjustment for confounding factors. COPD-related HRU during follow-up was described. Results: Among 4020 patients with COPD, 2164 initiated a specific therapy. Of these, 54.4% stopped treatment within 12 months. Persistence with all COPD therapy regimens was low, particularly for inhaled corticosteroid (ICS; 25.6%) and ICS/twice-daily long-acting beta-agonist (39.4%) regimens. Among 721 persistent patients who were matched with 721 non-persistent patients, there was no difference in the number of moderate or severe exacerbations at 12 months. However, medical procedures (for instance, pulmonary function testing and chest X-rays) were more frequently observed among persistent patients than among non-persistent patients, suggesting worse disease severity. Conclusion: Patients receiving specific treatment(s) for COPD demonstrated low persistence for all examined therapy regimens, with no clear impact of persistence status on the frequency of exacerbations at 12 months.
- 1 December 2019
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 14, 2905-2915
Open AccessImpact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
Purpose: This study assessed therapy persistence in patients with chronic obstructive pulmonary disease (COPD) in France, and the impact of non-persistence on exacerbations and described COPD-related healthcare resource use (HRU). Methods: Patients aged ≥45 years who received ≥1 dispensed bronchodilator per quarter over three consecutive quarters between 2007 and 2014 and initiated specific COPD therapy were selected from the Echantillon Généraliste des Bénéficiaires (EGB) database. Persistence, defined as the absence of dispensing gaps of >90 days, was measured at 12 months. Exacerbations were compared between persistent and non-persistent patients during follow-up after patient matching and adjustment for confounding factors. COPD-related HRU during follow-up was described. Results: Among 4020 patients with COPD, 2164 initiated a specific therapy. Of these, 54.4% stopped treatment within 12 months. Persistence with all COPD therapy regimens was low, particularly for inhaled corticosteroid (ICS; 25.6%) and ICS/twice-daily long-acting beta-agonist (39.4%) regimens. Among 721 persistent patients who were matched with 721 non-persistent patients, there was no difference in the number of moderate or severe exacerbations at 12 months. However, medical procedures (for instance, pulmonary function testing and chest X-rays) were more frequently observed among persistent patients than among non-persistent patients, suggesting worse disease severity. Conclusion: Patients receiving specific treatment(s) for COPD demonstrated low persistence for all examined therapy regimens, with no clear impact of persistence status on the frequency of exacerbations at 12 months.